Mediators of Inflammation

Mediators of Inflammation / 2015 / Article

Research Article | Open Access

Volume 2015 |Article ID 434692 |

Chen Li, Weijian Lun, Xinmei Zhao, Shan Lei, Yandong Guo, Jiayi Ma, Fachao Zhi, "Allicin Alleviates Inflammation of Trinitrobenzenesulfonic Acid-Induced Rats and Suppresses P38 and JNK Pathways in Caco-2 Cells", Mediators of Inflammation, vol. 2015, Article ID 434692, 11 pages, 2015.

Allicin Alleviates Inflammation of Trinitrobenzenesulfonic Acid-Induced Rats and Suppresses P38 and JNK Pathways in Caco-2 Cells

Academic Editor: Anshu Agrawal
Received30 Oct 2014
Revised04 Jan 2015
Accepted04 Jan 2015
Published02 Feb 2015


Background. Allicin has anti-inflammatory, antioxidative and proapoptotic properties. Aims. To evaluate the effects and investigate the mechanism of allicin on trinitrobenzenesulfonic acid-induced colitis, specifically with mesalazine or sulfasalazine. Methods. 80 rats were divided equally into 8 groups: control; trinitrobenzenesulfonic acid; allicin prevention; allicin; mesalazine; sulfasalazine; allicin + sulfasalazine, and mesalazine + allicin. Systemic and colonic inflammation parameters were analysed. In addition, protein and culture medium of Caco-2 cells treated with various concentrations of IL-1β or allicin were collected for investigation of IL-8, NF-κB p65 P38, ERK, and JNK. One-way ANOVA and Kruskal-Wallis test were used for parametric and nonparametric tests, respectively. Results. Allicin reduced the body weight loss of trinitrobenzenesulfonic acid-induced rats, histological score, serum TNF-α and IL-1β levels, and colon IL-1β mRNA level and induced serum IL-4 level, particularly in combination with mesalazine. In addition, 1 ng/mL IL-1β stimulated the P38, ERK, and JNK pathways, whereas pretreatment with allicin depressed this phenomenon, except for the ERK pathway. Conclusions. The inflammation induced by trinitrobenzenesulfonic acid is mitigated significantly by allicin treatment, particularly combined with mesalazine. Allicin inhibits the P38 and JNK pathways and the expression of NF-κB which explained the potential anti-inflammatory mechanisms of allicin.

1. Introduction

Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative disease (UC), is a nonspecific chronic disorder in the gut characterized by intestinal inflammation and mucosal damage. A systematic review of the incidence and prevalence of IBD indicated that the incidence of IBD in traditionally low prevalent regions, for instance, in Asia, has remarkably increased [1].

Current standard drug treatments for IBD include glucocorticosteroid, 5-aminosalicylates, sulfasalazine, immunosuppressor, infliximab, gene, and stem cell therapy. However, relapse and side effects, including allergy and granulocytopenia, remain during the whole treatment. Infliximab therapy appears to be safe and to have efficacious response and maintenance [2]; however, it is expensive and has some rare adverse effects, such as leukocytoclastic vasculitis and psoriasis [3, 4]. In addition, blocking one cytokine alone cannot inhibit or remove the coaction of multiple cytokines. Therefore, a much safer and more effective agent which is able to regulate upstream inflammatory pathways and subsequently suppress downstream cytokines is promising.

Garlic plays a crucial role in reducing infection, aging, and cardiovascular disease [5]. In addition, it has been reported that garlic may prevent colorectal tumor formation, reduce cholesterol and blood pressure, help to inhibit coagulation, and provide broad antioxidant activity to limit free radical damage [6]. An epidemiologic meta-analysis reported that a high intake of garlic may be associated with a protective effect against gastric cancer [7]. The intact garlic cloves contain alliinase and alliin in different compartments rather than allicin [8]. However, when the clove is cut or crushed, alliin and alliinase interact to form allicin which is responsible for the pungent odor of garlic and the antibiotic properties of garlic [6]. Allicin was first isolated and studied in the laboratory by Cavallito and Bailey in 1944 where it was found to have antibacterial properties [9]. It can induce apoptosis and the differential expression of proteins such as annexin I, galectin, and VDAC-1 in tumor cells [10]. It also modulates NF-κB transcriptional and DNA binding activity, suppresses NF-κB antiapoptotic target genes (Bcl-2, cIAP1/2) and inflammatory target genes (iNOS and COX-2), and consequently, as observed in human SW620 and HCT116 colon cancer cells, induces apoptosis [11]. As 1% of all cases of colorectal cancer occur in individuals with IBD [12, 13], it may be assumed that allicin may have a therapeutic effect on IBD.

CD is a T helper 1- (Th1-) mediated disease, with overproduction of IFN-γ and IL-12 [14, 15]. It is commonly thought that IL-12-mediated Th1 cell transmural colitis induced by trinitrobenzenesulfonic acid (TNBS) causes immunopathological human CD [16, 17]. To confirm the anti-inflammatory effects of allicin in vivo, the inflammatory index after administration of allicin and other proven anti-inflammatory drugs, namely, sulfasalazine and mesalazine, on TNBS-induced colitis in rats was investigated.

To study the mechanisms of the anti-inflammatory properties of allicin, the human colon adenocarcinoma cell line, Caco-2, was used. This is an ideal cell line to research the expression of proteins and functions of intestinal epithelial as this cell line imitates inflammatory status following stimulation with IL-1β. The phosphorylation of the P38, ERK, and JNK pathways was also accessed.

2. Materials and Methods

2.1. Induction of Colitis and Treatment of Rats

Eighty male Wistar rats (180–220 g, Experimental Animal Center of Southern Medical University, Guangzhou, China) were used in the study and acclimated under 12 h/12 h light-dark condition for 14 days. Animals were provided with ad libitum commercial rodent chow and had free access to drinking water. The study was approved by the Nanfang Hospital Animal Ethics Committee. On day 0, rats were anaesthetized with 2% pentobarbital sodium (Sigma-Aldrich, MO, USA), the catheter was carefully inserted into the colon (8 cm proximal to the anus), and TNBS mixture (diluted 1 : 1 in 100% ethanol) at 50 mg per kilogram body weight was slowly injected. For the control group (), the same volume of 50% ethanol was injected.

At 24 h after the enema, 60 rats were divided into 6 groups randomly ( each group) and were administered intragastrically with either saline; allicin (30 mg/kg, Cisen Pharmacy Company, Shandong, China); mesalazine (30 mg/kg, Ethypharm Industries, Saint-Cloud, France); sulfasalazine (100 mg/kg, Sine Pharmacy Company, Shanghai, China); allicin combined with mesalazine; or allicin combined with sulfasalazine at the same doses mentioned above. The final group () had been treated with allicin (30 mg/kg) for 2 weeks prior to the enema and was then treated with saline (allicin prevention group). The control group () treated with 50% ethanol alone was administered with saline. These procedures were repeated every 24 h.

All rats were weighed every other day and sacrificed on day 14 by anaesthetization and air-injection. The vitality and defecation of rats were observed. Blood and colonic tissue were processed as described below.

2.2. Macroscopic and Microscopic Assessment of Colonic Damage

The distal 8 cm of the rat colon and rectum was removed, opened longitudinally, washed, and then photographed. Following observation, full thickness specimens from inflamed tissue were fixed in 4% paraformaldehyde for 24 h, dehydrated, and embedded in paraffin. Tissue sections were cut at 4 μm, stained with hematoxylin/eosin (H&E), and evaluated by 2 independent experienced pathologists in a blinded fashion, using a histological score ranging from 0 to 3. This index was based on the degree of epithelial damage and ulceration (0 = no; 1 = erosion; 2 = ulcer), ulcer and infiltration depth (0 = no; 1 = submucosa; 2 = muscularis; 3 = serosa), and edema and mononuclear cells infiltration (0 = no; 1 = mild; 2 = moderate; 3 = severe).

2.3. RT-PCR Analysis for IL-1β mRNA in Colon

Expression of colon mRNA coding for the cytokine IL-1β was quantified by RT-PCR as follows. The total RNA of the colon samples was isolated with Trizol (Takara Bio, Shiga, Japan) according to the manufacturer’s protocol and used for the synthesis of first-strand cDNA using PrimeScript RT reagent Kit (Takara Bio, Shiga, Japan). The RT product was amplified by PCR with Ex Taq (Takara Bio, Shiga, Japan) and specific primers were as follows: IL-1β forward primer, 5′-TGA CCC ATG TGA GCT GAA AG-3′; reverse primer, 5′-GAA GAC AAA CCG CTT TTC CA-3′; β-actin forward primer, 5′-TGT CAC CAA CTG GGA CGA TA-3′; reverse primer, 5′-AAC ACA GCC TGG ATG GCT AC-3′. The lengths of the expected products were 241 bp for IL-1β and 195 bp for β-actin. The results were carried out 3 times and presented by intensity analysis and agarose gel electrophoresis.

2.4. Cell Cultures and Allicin Treatment

The Caco-2 cell line was obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were grown at 37°C in 5% CO2 in high glucose DMEM (Gibco-BRC, NY, USA) supplemented with 100 μg/mL streptomycin, 100 IU/mL penicillin (Genom, Zhejiang, China), and 10% fetal bovine serum (FBS) (Gibco-BRC, NY, USA). Cells were seeded at a density of cells/mL onto six-well tissue culture plates 48 h prior to assay.

After 24 h serum-free starvation, cells were treated with 0.1, 1, or 10 ng/mL of human recombinant IL-1β (Cell Signaling Technology, MA, USA) for 12 h, 24 h, or 48 h. Untreated Caco-2 cells served as control. 10 μg/mL or 25 μg/mL allicin was added with or without the IL-1β stimulation 2 h prior. The culture supernatant was collected and the cells were harvested for the following investigations.

2.5. MTT Assay

Approximately cells were seeded into 96-well culture plates and had been treated with or without IL-1β or allicin for 12, 24, or 48 h, respectively. After adding 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich, MO, USA) and the incubation, the absorbency at 490 nm was measured using microplate reader (Bio-Rad, CA, USA). The experiments were carried out for at least 3 times.

2.6. Western Blot Analysis

We separated nuclear and cytoplasmic protein of the harvested cells and then detected the levels of NF-κB p65 (C22B4) subunit and histones 2A (D603A, 1 : 1000, Cell Signaling Technology, MA, USA) in the nucleus. The cells were also lysed in 200 μL of lysis buffer (Beyotime, Jiangsu, China) with 1 mmol/L PMSF (Beyotime, Jiangsu, China) and phosphatase inhibitor cocktail (Cell Signaling Technology, MA, USA). Total protein was resolved on 12% SDS-PAGE gels and transferred to 0.45 μm PVDF membranes (Millipore, Darmstadt, Germany). Western blot analysis was performed to determine cellular levels of p-P38 (D3F9), P38, p-ERK (D13.14.4E), ERK (137F5), p-JNK (81E11), JNK (56G8) (1 : 1000, Cell Signaling Technology, MA, USA), and β-actin (C4, 1 : 1000, ZSBIO, Beijing, China). Bands were visualized with secondary HRP-conjugated antibodies (1 : 3000, ZSBIO, Beijing, China) and the ECL system (Millipore, Darmstadt, Germany). Anti-H2A and β-actin were used to show equal sample loading. All the tests were carried out for at least 3 times.

2.7. ELISA Assay

Serum and cell culture medium were diluted with assay diluent. TNF-α (sensitivity: 5 pg/mL), IL-1β (sensitivity: 5 pg/mL), IL-4 (sensitivity: 0.2 pg/mL) and IL-10 (sensitivity: 1.5 pg/mL) levels in rats’ serum and IL-8 (sensitivity: 7.5 pg/mL) level in cell culture medium were examined by commercial ELISA kits (eBioscience, CA, USA; R&D systems, MN, USA). Kits are specific for natural and recombinant rat TNF-α, IL-1β, IL-4, IL-10 and human IL-8, respectively.

2.8. Statistics

Experiments were performed at least three times. Data was processed and analyzed using the SPSS 13.0 software (Chicago, IL, USA). The results were expressed as mean ± standard deviation (SD). Parametric data were analyzed using one-way analysis of variance (ANOVA) followed by LSD-t or Dunnett T3 post hoc tests, as appropriate. The Kruskal-Wallis test was performed to assess categorical data. The body weight was evaluated by covariance analysis. A value of was considered statistically significant.

3. Results

3.1. Allicin, Particularly in Combination with Mesalazine, Alleviates TNBS-Induced Colitis in Rats

TNBS-induced colitis in rats displayed marked edema bleeding, intestinal mucosa thickening, and ulcers (Figure 1(a)). Intragastric gavage with allicin, sulfasalazine, or mesalazine for two weeks facilitated the healing of TNBS-induced colitis. Moreover, allicin combined with sulfasalazine or mesalazine reversed the damage of the colon. Rats in the allicin, mesalazine, and mesalazine + allicin groups showed less body weights loss compared with TNBS group at day 14 (Figure 1(b)). However, all the drugs did not alter the fatality rate of TNBS-induced rats significantly (, ).

3.2. Allicin Histologically Improved the TNBS-Induced Colitis

Control group colons showed minimal numbers of lymphocytes in the lamina propria and regularly arranged crypts. In addition, there was no inflammatory infiltration in the submucosa (Figure 2). The TNBS edema led to severe colitis with deep ulceration, transmural leukocyte infiltration, and loss of goblet cells. Two weeks after various treatments, considerable evidence of regeneration was seen. The Kruskal-Wallis test was used to analyze the H&E staining score and the result was presented by mean rank (Table 1). The severer the inflammation was, the higher the rank was. There was a significant difference among the groups (, ) with the mean rank of the control group being the lowest (mean rank = 6.06) whilst that of the TNBS with saline treatment group being the highest (mean rank = 57.75). Among the treatment groups, the rank of the mesalazine + allicin group was the lowest (mean rank = 22.30).

GroupsScoreMean rank order

Control ( = 10)0.22 ± 0.4416.06
TNBS ( = 6)5.83 ± 0.75357.75
Allicin prevention ( = 7)4.29 ± 0.75645.14
Allicin ( = 7)4.29 ± 1.11344.50
Sulfasalazine ( = 9)2.22 ± 0.97223.33
Sulfasalazine + allicin ( = 8)3.38 ± 1.40835.50
Mesalazine ( = 6)3.33 ± 0.81634.75
Mesalazine + allicin ( = 10)2.10 ± 1.19722.30


The Kruskal-Wallis test was performed to assess the histological scores.

3.3. Allicin Combined with Mesalazine Downregulated Proinflammatory Cytokines and Upregulated Anti-Inflammatory Cytokines

Serum TNF-α and IL-1β levels were decreased in the treatment groups compared with that of the TNBS group (, , resp.; ) (Figures 3(a) and 3(b)). In particular, concentrations of them in the mesalazine + allicin groups were the lowest (, , resp.), and there were no significant differences between the control group and the mesalazine + allicin group (). IL-β mRNA levels were also reduced significantly in the mesalazine + allicin group (, ). Among the treatment groups, IL-β mRNA levels were notably low in sulfalazine + allicin and mesalazine + allicin, between which no significant difference was found () (Figures 4(a) and 4(b)). Moreover, we also found that both the sulfasalazine and the mesalazine + allicin group significantly increased the IL-4 secretion after the edema compared to the TNBS group (, , resp.; ) but not that of IL-10 (Figures 3(c) and 3(d)).

3.4. Allicin Alleviates Nuclear NF-B p65 Expression and Inhibits the P38 and JNK Pathways in IL-1-Treated Caco-2 Cells

In the MTT assay, treatment with 50 ng/mL allicin inhibited Caco-2 cell growth with 24 h incubation and this suppression of cell growth was enhanced with prolonged incubation and increased concentration of allicin (data not shown). Then we used ELISA to measure the levels of IL-8 and western blot to detect nuclear NF-κB p65 in 0.1 ng/mL, 1 ng/mL, and 10 ng/mL IL-1β-treated Caco-2 cells at 12 h, 24 h, and 48 h. As shown in Figures 5(a), 6(a), and 6(b), IL-1β treatment promoted the secretion of IL-8 and NF-κB p65 expression in the nucleus, which was enhanced by increased concentration of IL-1β at the 12 h and 24 h time points.

Allicin was given to investigate its anti-inflammation effect in vitro. It is shown that 10 and 25 μg/mL allicin did not affect the level of IL-8 in the medium but downregulated the expression of nuclear NF-κB p65 of IL-1β-treated cells at 12 h and 24 h time points (Figures 5(b), 6(c), and 6(d)).

Following the above experiments, 25 μg/mL allicin was chosen as the appropriate concentration and 24 h as the appropriate treatment time point. The change of P38, ERK, and JNK in response to allicin treatment in IL-1β-induced Caco-2 cells was also investigated (Figure 7). In 1 ng/mL IL-1β stimulated Caco-2 cells, the P38, ERK, and JNK pathways were stimulated by phosphorylation. 25 μg/mL allicin significantly inhibited the P38 and JNK pathways induced by IL-1β, whilst it did activate the ERK pathway with and without IL-1β.

3.5. The P38 and JNK Pathways Were Inhibited by Allicin

As observed in the above experiment, allicin could decrease the expression of nuclear NF-κB p65, a downstream target of the mitogen-activated protein kinase (MAPK) pathways, in IL-1β-treated cells. To further study the mechanism of the anti-inflammatory effect of allicin, the change of P38, ERK, and JNK in response to allicin treatment in IL-1β-induced Caco-2 cells was investigated (Figure 6). In 1 ng/mL IL-1β stimulated Caco-2 cells, the P38, ERK, and JNK pathways were stimulated by phosphorylation. Whilst 25 μg/mL allicin alone did not significantly inhibit the P38 and JNK pathways, it did activate the ERK pathway with and without IL-1β.

4. Discussion

TNBS-induced colitis is a widely used animal model for investigating the mechanism of acute or chronic colitis. It normally causes mucosal inflammation, intestinal ulcers, and histological damage and triggers colonic expression of the proinflammatory cytokines TNF-α, IL-1β, and IL-6 in 14 days after the TNBS administration [18]. In our study, we successfully established TNBS-induced colitis by enema and then treated rats with allicin, sulfasalazine, and mesalazine alone or in various combinations. Fatality rate, body weight, colon histological H&E staining scores, colon IL-1β mRNA levels, and serum cytokine levels were assessed in TNBS-treated rats. It is exciting to find that allicin alone or combined with mesalazine significantly improve the TNBS-induced colitis, which brings valuable clue for clinic treatment strategies of IBD.

Allicin, extracted from garlic, has anti-infection, antioxidative, antitumorigenesis, and proapoptotic properties [5, 6, 10, 11]. The focus of the current study was the anti-inflammatory effect of allicin, particularly when combined with sulfasalazine or mesalazine, and the possible mechanisms behind this process.

High levels of proinflammatory cytokines, such as TNF-α, IL-1, and IL-8 induce, amplify and prolong intestinal inflammation [19]. The potent cytokine IL-1 activates many immune and inflammatory cells. It is produced by various cell types including monocytes, neutrophils, and endothelial cells [20, 21]. In TNBS-treated rats, colonic mRNA levels of TNF-α and IL-1β are increased significantly [22]. Similarly, in the current study, TNBS-treated rats displayed the same tendency with an increase in serum TNF-α and IL-1β levels, as well as colon IL-1β mRNA levels, all of which were decreased following allicin treatment and in particular following treatment with allicin combined with mesalazine.

IL-4 and IL-10 have immunoregulatory and anti-inflammatory properties in gut immunology [23, 24]. In the current study, allicin did not alter serum IL-4 levels; however, sulfasalazine treatment and allicin combined with mesalazine significantly promoted them. But the serum levels of IL-10 were not altered by any of the treatment drugs, most likely because these drugs fell short of varying IL-10 levels. A research about the proinflammatory effect of allicin on mice with malaria infection, intraperitoneally injected with P. yoelii 17XL, also showed that it did not cause major changes of IL-10 levels of splenocytes supernatants.

Although the tendencies of different inflammatory indices were not accordant among the treatment groups in the current study, it could still be inferred that allicin relieves the inflammation of TNBS-induced colitis, particularly when combined with mesalazine. This might be because variant drugs regulate diverse inflammatory targets. The H&E score and serum TNF-α and IL-1β levels of sulfasalazine group were lower than sulfasalazine + allicin group, and serum IL-4 level of sulfasalazine group was higher than sulfasalazine + allicin group, possibly because the two compounds compete the inflammatory targets each other.

Caco-2 cell line was used in the in vitro experiments for it was more responsive to IL-1β compared to TNF-α or lipopolysaccharide (LPS) [25]. IL-8, the neutrophil chemoattractant and activator [23], is increased in diseased mucosa [26]. In addition, the level of IL-8 correlates with the macroscopic grade of local inflammation and neutrophil numbers in mucosal tissue, particularly in patients with UC [27]. Increased expression of NF-κB is the key in the development of IBD. Stimulation of NF-κB induces the phosphorylation, ubiquitination, and degradation of IκB, which phosphorylates NF-κB p65 subunit on Ser276, and then promotes nuclear translocation and subsequent DNA binding. Together, these processes promote downstream IL-1β and TNF-α expression which can then activate NF-κB further, so that the inflammatory state develops gradually [2830]. In the current study, IL-1β increased secretion of IL-8 and nuclear NF-κB p65 expression with increased concentration and increased time. When the appropriate amount of allicin was added 2 h prior to IL-1β stimulation, IL-8 production was not significantly altered; however, nuclear NF-κB p65 expression was suppressed by allicin, particularly at a high dose. As cytokines in the network interact with each other, IL-8 could be influenced by the change of IL-1β and TNF-α caused by the variable p65 submit translocation. These results further support an anti-inflammatory role for allicin, possibly via one of the MAPK pathways, as NF-κB is the target of the MAPK pathways.

Three important MAPK pathways, P38, ERK, and JNK, were investigated in the current study. These pathways regulate diverse processes ranging from proliferation and differentiation to apoptosis [31]. Activation of P38 is characteristically and greatly increased in mucosal biopsies from patients with active IBD, followed by the activation of multiple proinflammatory cytokines [32]. Meanwhile, the JNK pathway plays crucial roles in regulating responses to various stresses and in the response of epithelial cells to stress conditions [33], neural development, inflammation, and apoptosis. IL-1 stimulation has been shown to strongly activate JNK [34] which in turn mediates the phosphorylation of c-Jun [33]. The present study showed that allicin downregulates the phosphorylation of P38 and JNK and the expression of NF-κB p65 in Caco-2 cells, which were all elevated following IL-1β treatment (Figures 6(c), 6(d), and 7). It can therefore be concluded that allicin performs an anti-inflammatory role through reducing NF-κB and suppressing the P38 and JNK pathways. The probable mechanism is allicin works on the kinase upstream, and then P38 and JNK regulate downstream target NF-κB. A study focusing on diallyl disulfide (DADS) [35], a component of garlic, indicated that addition of 25, 50, 100, and 500 μmol/L DADS to human colorectal cancer cells (HCT-15 cells) elevates ERK phosphorylation by 39, 52, 73, and 61%, respectively. Concurrently, there were no differences in ERK expression in cultures grown in the presence or absence of DADS. The addition of DADS also decreased the proportion of HCT-15 cells in the G1 phase and increased the proportion of cells in the G2M phase [36]. As allicin activated the ERK pathway in the current study, it is possible that the anti-inflammatory mechanism of allicin is via the mediation of apoptosis through activation of the ERK pathway.

5. Conclusions

In this study, we found that the TNBS-induced inflammation in rats is mitigated significantly by allicin treatment, particularly when combined with mesalazine. It is likely that allicin treatment, as observed by the decreased expression of NF-κB, inhibits the P38 and JNK pathways whilst activating the ERK pathway and mediating apoptosis. However, the present research has limitation. Although allicin has therapeutic effect of experimental colitis, we do not know whether it is capable of curing patients with IBD since any animal model can rarely imitate the real situation of a patient. As current standard drug treatments for IBD often result in relapse and adverse side effects or are extremely expensive, allicin, as a regulator of upstream inflammatory pathways and the subsequential suppression of downstream cytokines, may be a much safer and effective agent in the treatment of IBD after a rigorous clinical trial.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper. There is no potential conflict of interests for each of the authors and therapeutic drugs.

Authors’ Contribution

Chen Li designed and carried out the studies and drafted the paper. Weijian Lun, Shan Lei, and Yandong Guo participated in the animal experiments and samples analyses. Xinmei Zhao assisted in designing the study. Jiayi Ma performed the revision of the paper. Fachao Zhi assisted in designing the study and coordinating and critically reviewing the paper.


This study was supported by the National Natural Science Foundation of China (Grant no. 81370502 to Professor Fachao Zhi). Dr. Zhaoxia Zhang also participated in the animal experiments and samples analyses.


  1. N. A. Molodecky, I. S. Soon, D. M. Rabi et al., “Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review,” Gastroenterology, vol. 142, no. 1, pp. 46.e42–54.e42, 2012. View at: Publisher Site | Google Scholar
  2. O. J. Adedokun, W. J. Sandborn, B. G. Feagan et al., “Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis,” Gastroenterology, vol. 147, no. 6, pp. 1296–1307, 2014. View at: Publisher Site | Google Scholar
  3. S. Karoui, N. Bibani, I. B. Gorbel et al., “Leukocytoclastic vasculitis: a rare adverse effect secondary to infliximab,” Inflammatory Bowel Diseases, vol. 17, no. 2, pp. E4–E5, 2011. View at: Publisher Site | Google Scholar
  4. M. Iborra, B. Beltrán, G. Bastida, M. Aguas, and P. Nos, “Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect,” Journal of Crohn's and Colitis, vol. 5, no. 2, pp. 157–161, 2011. View at: Publisher Site | Google Scholar
  5. A. A. Powolny and S. V. Singh, “Multitargeted prevention and therapy of cancer by diallyl trisulfide and related Allium vegetable-derived organosulfur compounds,” Cancer Letters, vol. 269, no. 2, pp. 305–314, 2008. View at: Publisher Site | Google Scholar
  6. D. H. Alpers, “Garlic and its potential for prevention of colorectal cancer and other conditions,” Current Opinion in Gastroenterology, vol. 25, no. 2, pp. 116–121, 2009. View at: Publisher Site | Google Scholar
  7. Y. Zhou, W. Zhuang, W. Hu, G. Liu, T. Wu, and X. Wu, “Consumption of large amounts of Allium vegetables reduces risk for gastric cancer in a meta-analysis,” Gastroenterology, vol. 141, no. 1, pp. 80–89, 2011. View at: Publisher Site | Google Scholar
  8. W. Zhang, M. Ha, Y. Gong, Y. Xu, N. Dong, and Y. Yuan, “Allicin induces apoptosis in gastric cancer cells through activation of both extrinsic and intrinsic pathways,” Oncology Reports, vol. 24, no. 6, pp. 1585–1592, 2010. View at: Publisher Site | Google Scholar
  9. C. J. Cavallito and J. H. Bailey, “Allicin, the antibacterial principle of Allium sativum. I. Isolation, physical properties and antibacterial action,” Journal of the American Chemical Society, vol. 66, no. 11, pp. 1950–1951, 1944. View at: Publisher Site | Google Scholar
  10. N. Li, R. Guo, W. Li et al., “A proteomic investigation into a human gastric cancer cell line BGC823 treated with diallyl trisulfide,” Carcinogenesis, vol. 27, no. 6, pp. 1222–1231, 2006. View at: Publisher Site | Google Scholar
  11. J. O. Ban, D. Y. Yuk, K. S. Woo et al., “Inhibition of cell growth and induction of apoptosis via inactivation of NF-κB by a sulfurcompound isolated from garlic in human colon cancer cells,” Journal of Pharmacological Sciences, vol. 104, no. 4, pp. 374–383, 2007. View at: Publisher Site | Google Scholar
  12. T. Jess, E. V. Loftus Jr., F. S. Velayos et al., “Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen County, Denmark and Olmsted County, Minnesota,” The American Journal of Gastroenterology, vol. 102, no. 4, pp. 829–836, 2007. View at: Publisher Site | Google Scholar
  13. T. L. Zisman and D. T. Rubin, “Colorectal cancer and dysplasia in inflammatory bowel disease,” World Journal of Gastroenterology, vol. 14, no. 17, pp. 2662–2669, 2008. View at: Publisher Site | Google Scholar
  14. J. Yamashita, C. Iwamura, T. Ito et al., “Paraoxonase-1 suppresses experimental colitis via the inhibition of IFN-γ production from CD4 T cells,” The Journal of Immunology, vol. 191, no. 2, pp. 949–960, 2013. View at: Publisher Site | Google Scholar
  15. P. Biancheri, A. Di Sabatino, F. Ammoscato et al., “Absence of a role for interleukin-13 in inflammatory bowel disease,” European Journal of Immunology, vol. 44, no. 2, pp. 370–385, 2014. View at: Publisher Site | Google Scholar
  16. C. O. Elson, K. W. Beagley, A. T. Sharmanov et al., “Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance,” Journal of Immunology, vol. 157, no. 5, pp. 2174–2185, 1996. View at: Google Scholar
  17. G. P. Morris, P. L. Beck, M. S. Herridge, W. T. Depew, M. R. Szewczuk, and J. L. Wallace, “Hapten-induced model of chronic inflammation and ulceration in the rat colon,” Gastroenterology, vol. 96, no. 3, pp. 795–803, 1989. View at: Google Scholar
  18. S. Wirtz, C. Neufert, B. Weigmann, and M. F. Neurath, “Chemically induced mouse models of intestinal inflammation,” Nature Protocols, vol. 2, no. 3, pp. 541–546, 2007. View at: Publisher Site | Google Scholar
  19. M. F. Neurath, “Cytokines in inflammatory bowel disease,” Nature Reviews Immunology, vol. 14, no. 5, pp. 329–342, 2014. View at: Publisher Site | Google Scholar
  20. C. Garlanda, C. A. Dinarello, and A. Mantovani, “The interleukin-1 family: back to the future,” Immunity, vol. 39, no. 6, pp. 1003–1018, 2013. View at: Publisher Site | Google Scholar
  21. M. G. Netea, F. L. van de Veerdonk, J. W. M. van der Meer, C. A. Dinarello, and L. A. B. Joosten, “Inflammasome-independent regulation of IL-1-family cytokines,” Annual Review of Immunology, vol. 1, pp. 3.1–3.29, 2014. View at: Publisher Site | Google Scholar
  22. Y. Karrout, L. Dubuquoy, C. Piveteau et al., “In vivo efficacy of microbiota-sensitive coatings for colon targeting: a promising tool for IBD therapy,” Journal of Controlled Release, vol. 197, pp. 121–130, 2015. View at: Publisher Site | Google Scholar
  23. G. Rogler and T. Andus, “Cytokines in inflammatory bowel disease,” World Journal of Surgery, vol. 22, no. 4, pp. 382–389, 1998. View at: Publisher Site | Google Scholar
  24. M.-C. Li and S.-H. He, “IL-10 and its related cytokines for treatment of inflammatory bowel disease,” World Journal of Gastroenterology, vol. 10, no. 5, pp. 620–625, 2004. View at: Google Scholar
  25. B. Romier, J. van de Walle, A. During, Y. Larondelle, and Y.-J. Schneider, “Modulation of signalling nuclear factor-κB activation pathway by polyphenols in human intestinal Caco-2 cells,” British Journal of Nutrition, vol. 100, no. 3, pp. 542–551, 2008. View at: Publisher Site | Google Scholar
  26. R. Daig, T. Andus, E. Aschenbrenner, W. Falk, J. Schölmerich, and V. Gross, “Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease,” Gut, vol. 38, no. 2, pp. 216–222, 1996. View at: Publisher Site | Google Scholar
  27. L. Mazzucchelli, C. Hauser, K. Zgraggen et al., “Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation,” The American Journal of Pathology, vol. 144, no. 5, pp. 997–1007, 1994. View at: Google Scholar
  28. M. S. Hayden and S. Ghosh, “Shared principles in NF-κB signaling,” Cell, vol. 132, no. 3, pp. 344–362, 2008. View at: Publisher Site | Google Scholar
  29. E. G. Maiorov, O. Keskin, A. Gursoy, and R. Nussinov, “The structural network of inflammation and cancer: merits and challenges,” Seminars in Cancer Biology, vol. 23, no. 4, pp. 243–251, 2013. View at: Publisher Site | Google Scholar
  30. D. L. Boone, E. G. Lee, S. Libby et al., “Recent advances in understanding: NF-κB regulation,” Inflammatory Bowel Diseases, vol. 8, no. 3, pp. 201–212, 2002. View at: Publisher Site | Google Scholar
  31. M. Qi and E. A. Elion, “MAP kinase pathways,” Journal of Cell Science, vol. 118, no. 16, pp. 3569–3572, 2005. View at: Publisher Site | Google Scholar
  32. J. Epstein, G. Docena, T. T. MacDonald, and I. R. Sanderson, “Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1β and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease,” British Journal of Nutrition, vol. 103, no. 6, pp. 824–832, 2010. View at: Publisher Site | Google Scholar
  33. G. L. Johnson and R. Lapadat, “Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases,” Science, vol. 298, no. 5600, pp. 1911–1912, 2002. View at: Publisher Site | Google Scholar
  34. C. Dong, R. J. Davis, and R. A. Flavell, “MAP kinases in the immune response,” Annual Review of Immunology, vol. 20, pp. 55–72, 2002. View at: Publisher Site | Google Scholar
  35. L. M. Knowles and J. A. Milner, “Diallyl disulfide induces ERK phosphorylation and alters gene expression profiles in human colon tumor cells,” Journal of Nutrition, vol. 133, no. 9, pp. 2901–2906, 2003. View at: Google Scholar
  36. L. M. Knowles and J. A. Milner, “Depressed p34cdc2 kinase activity and G2/M phase arrest induced by diallyl disulfide in HCT-15 cells,” Nutrition and Cancer, vol. 30, no. 3, pp. 169–174, 1998. View at: Publisher Site | Google Scholar

Copyright © 2015 Chen Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.